Tregs that mainly differentiate from the naïve T-cell fraction to suppress excessive activation of T cells are described as CD25+ FOXP3+ CD4 T cells and function to suppress antitumor immunity by effector T cells in the tumor microenvironment [74]. The gene discussed is CD4; the disease is neoplasm.